Clinical Trial Update: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab in younger patients with refractory or relapsed neuroblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• Neuroblastoma

Drugs mentioned

• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• Temozolomide (Temozolomide)
• Temsirolimus (temsirolimus)
• dinutuximab (dinutuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 2 | Status: COMPLETED | Results posted: 2019-11-18